Clinical Application of Stem Cells in Regeneration Medicine—Part II

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Clinical Laboratory Medicine".

Deadline for manuscript submissions: 20 September 2024 | Viewed by 842

Special Issue Editor


E-Mail Website
Guest Editor
Unidad de Gestión Clínica de Endocrinología y Nutrición - GC17, Instituto Maimónides de Investigación Biomédica de Córdoba, Hospital Universitario Reina Sofía, CIBERFES, Avda. Menéndez Pidal s/n, 14004 Córdoba, Spain
Interests: mesenchymal stem cells; regenerative medicine; diabetes; wound healing; exosomes; extracellular vesicles; aging
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The purpose of regenerative medicine is to restore the structure and function of damaged tissues or organs. In the body, different types of stem cells distributed in several tissues maintain homeostasis and tissue regenerative capacity. Stem cells have been isolated and expanded from different sources, including bone marrow, adipose tissue, and umbilical cords. Due to their differentiation and immunomodulatory capacity, the use of stem cells as a tool in regenerative medicine has been expanding. Stem cells are currently being used in the clinic through cell therapy techniques by means of autologous or allogeneic transplantation. Thus, thousands of studies related to stem cells and cell therapy can currently be found in the ClinicalTrials.gov database. In addition to cell therapy, the induction of the mobilization of circulating stem cells is another strategy to favor the regeneration of damaged tissues. Along with these possibilities, stem-cell-derived extracellular vesicles have recently been shown to have immunomodulatory and regenerative properties. This is allowing for the development of cell-free therapies for regenerative purposes. In view of the increasing knowledge of the possible alternatives for the use of stem cells at the clinical level, the aim of this Special Issue is to share the latest advances in the clinical application of stem cells or their extracellular vesicles in regenerative medicine.

Dr. Antonio Casado-Díaz
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • stem cells
  • regenerative medicine
  • extracellular vesicles
  • cell therapy
  • stem cell preconditioning
  • stem cell mobilization

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 6466 KiB  
Article
The Effect of Cell Culture Passage on the Efficacy of Mesenchymal Stromal Cells as a Cell Therapy Treatment
by MDolores Carmona-Luque, Antonio Ballesteros-Ribelles, Alejandro Millán-López, Alfonso Blanco, Sonia Nogueras and Concha Herrera
J. Clin. Med. 2024, 13(9), 2480; https://doi.org/10.3390/jcm13092480 - 24 Apr 2024
Viewed by 536
Abstract
Background/Objective: Mesenchymal Stromal Cells (MSCs) have been considered a promising treatment for several diseases, such as cardiac injuries. Many studies have analyzed their functional properties; however, few studies have characterized MSCs through successive culture passages. The main objective of this work was to [...] Read more.
Background/Objective: Mesenchymal Stromal Cells (MSCs) have been considered a promising treatment for several diseases, such as cardiac injuries. Many studies have analyzed their functional properties; however, few studies have characterized MSCs through successive culture passages. The main objective of this work was to analyze the phenotype and functionality of MSCs isolated from two different sources in five culture passages to determine if the culture passage might influence the efficacy of MSCs as a cell therapy treatment. Methods: Bone Marrow (BM)-MSCs were harvested from the femur of Wistar rats (n = 17) and Adipose Tissue(AT)-MSCs were isolated from inguinal fat (n = 17). MSCs were cultured for five culture passages, and the immunophenotype was analyzed by flow cytometry, the functionality was characterized by adipogenic, osteogenic, and chondrogenic differentiation assays, and cytokine secretion capacity was determined through the quantification of the Vascular Endothelial Growth-Factor, Fibroblast Growth-Factor2, and Transforming Growth-Factorβ1 in the cell supernatant. The ultrastructure of MSCs was analyzed by transmission electron microscopy. Results: BM-MSCs exhibited typical phenotypes in culture passages two, four, and five, and their differentiation capacity showed an irregular profile throughout the five culture passages analyzed. AT-MSCs showed a normal phenotype and differentiation capacity in all the culture passages. BM- and AT-MSCs did not modify their secretion ability or ultrastructural morphology. Conclusions: Throughout the culture passages, BM-MSCs, but not AT-MSCs, exhibited changes in their functional and phenotypic characteristic that might affect their efficacy as a cell therapy treatment. Therefore, the culture passage selected should be considered for the application of MSCs as a cell therapy treatment. Full article
(This article belongs to the Special Issue Clinical Application of Stem Cells in Regeneration Medicine—Part II)
Show Figures

Graphical abstract

Back to TopTop